Sex steroids and bone mass. A study of changes about the time of menopause.

C Slemenda; S L Hui; C Longcope; C C Johnston

doi:10.1172/JCI113201

Department of Medicine, Regenstrief Institute, Indiana University School of Medicine, Indianapolis 46202.

Find articles by Slemenda, C. in: PubMed | Google Scholar

Department of Medicine, Regenstrief Institute, Indiana University School of Medicine, Indianapolis 46202.

Find articles by Hui, S. in: PubMed | Google Scholar

Department of Medicine, Regenstrief Institute, Indiana University School of Medicine, Indianapolis 46202.

Find articles by Longcope, C. in: PubMed | Google Scholar

Department of Medicine, Regenstrief Institute, Indiana University School of Medicine, Indianapolis 46202.

Find articles by Johnston, C. in: PubMed | Google Scholar

Published in Volume 80, Issue 5 on November 1, 1987
J Clin Invest. 1987;80(5):1261–1269. https://doi.org/10.1172/JCI113201.
© 1987 The American Society for Clinical Investigation

Published November 1, 1987 - Version history

To examine the relationships between bone loss and sex steroids, 84 peri- and postmenopausal women were studied at 4-mo intervals for 3 yr. At each visit, measurements were made of bone mass at the midshaft and distal radius, of steroids, of gonadotropins, and of bone gla protein (BGP). Bone loss was approximately 1% per yr among late perimenopausal and postmenopausal groups, whereas the early perimenopausal group lost no bone. Mean serum estrogen and BGP concentrations predicted rates of bone loss. BGP was negatively correlated with the rate of bone loss (r = -0.45) and with mean estrogen concentrations (r = -0.40). Multivariate regressions showed estrogen concentrations to be strong independent predictors of the slope of bone mass over time. When BGP concentrations were added to the models, the significance of estrogen was reduced, suggesting that a portion of the estrogen effect was mediated through effects on rates of bone remodelling.